• Derivatives Summary :

FIIs trend in derivatives
Instruments Buy[Rs.Cr] Sell[Rs.Cr] Net Positions [Rs.Cr] Contracts ['000s] Value[Rs.Cr]
Index Futures 33,680.00 54,057.00 33.00 258.78 10,518.55
Index Options 260,609.00 238,707.00 260.00 1,493.47 60,433.08
Stock Futures 42,846.00 62,474.00 42.00 1,293.08 48,186.30
Stock Futures 42,766.00 42,526.00 42.00 60.64 2,238.82
News

Blue star: Service Tax Dept imposes penalty of Rs.67.86 crore

India Infoline News Service May-02-2016

he company strongly believes that the said order apart from being patently erroneous, has been passed without appropriately considering the submissions made by the company and is based on incorrect presumptions and hence is untenable.

Alembic Pharma tumbles 2% despite FDA go-ahead for partial onset seizures drug

India Infoline News Service May-02-2016

he company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lacosamide Tablets, SO mg, 100 mg, lSO mg and 200 mg.

University of Nebraska (USA) honored Bhavarlal Jain

India Infoline News Service May-02-2016

he University of Nebraska (USA) has named their research project as Bhavarlal Hiralal Jain- University of Nebraska Water for Food Collaborative Program, permanently, to honour Bhavarlaljis pioneering efforts starting a new green revolution through his achievements in effective research, sustainable use of natural resources by bringing together farmers, agronomists, scientists, technologists and industrialists for the same noble cause.

Aviation stocks end on a mixed note; Interglobe Aviation slumps 5%

India Infoline News Service May-02-2016

he prices of non-subsidised cooking gas, non-PDS (public distribution system) kerosene and aviation turbine fuel (ATF) were increased on Sunday.

Marksans Pharma ends 10% higher on FDA nod for diabetes drug

India Infoline News Service May-02-2016

he company announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended Release (ER) Tablets USP 500 mg and 750 mg.

L&T Finance rallies 5% on Q4 results

India Infoline News Service May-02-2016

he company posted a net profit of Rs.2368.523 mn for the quarter ended March 31, 2016 compared with Rs.2055.591 mn for the quarter ended March 31, 2015.

Indian Equities News
Latest

Sensex, Nifty end in red…Nifty below 200-DMA

India Infoline News Service / 16:27, May 02, 2016

Commenting on the same, Amar Ambani, Head of Research at IIFL, said, “Deposit growth was strong at 17% yoy with CASA deposits growing slightly ahead. Sustained strong traction in savings deposits was impressive and the SA ratio stood at a historic high of 32%. If economic recovery gains momentum from FY18, then RoA delivery could reach 1.6% in FY19 aided by a substantially improved business franchise and improved credit environment. Striping the valuation of subsidiaries, the stand‐alone bank is trading at an undemanding valuation of 1.1x FY18 P/ABV. A highly capitalized balance sheet and headroom to generate profits through divestment of stake in subsidiaries provides high comfort about the bank’s ability to absorb credit shocks.”